The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells. Invest New Drugs 2013;31(2):458-60.
. Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB. Clin Nutr 2013;32(2):259-64.
. Presence of CTAK/CCL27, MCP-3/CCL7 and LIF in human colostrum and breast milk. Cytokine 2013;61(1):26-8.
. Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. J Cell Physiol 2012;227(5):1829-37.
. Editorial: innovative therapeutic approaches for the treatment of pediatric autoimmune and inflammatory diseases. Curr Pharm Des 2012;18(35):5728.
. Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. PLoS One 2012;7(6):e39543.
. The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans. Clin Nutr 2012;31(6):1018-21.
. Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Invest New Drugs 2012;30(4):1731-5.
. In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. Invest New Drugs 2012;30(1):405-7.
. JCV+ Patients with Inflammatory bowel disease show elevated plasma levels of MIG and SCF. Inflamm Bowel Dis 2012;18(6):1194-6.
. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. Br J Haematol 2012;157(4):510-4.
. The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation. Hum Immunol 2012;73(4):342-5.
.